Eton Pharmaceuticals, Inc.
ETON · Price history
Price at last available close
$51.16
−$8.02 (-13.55%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Eton Pharmaceuticals, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis.
How they make money
Eton Pharmaceuticals is a specialty pharmaceutical company that focuses on the development and commercialization of treatments for rare diseases. The company identifies existing molecules with known safety and efficacy profiles, pursues regulatory approval for new indications or improved formulations, and leverages a specialized sales force to market these products to healthcare professionals.
Products & services
The company markets ten rare disease products including KHINDIVI, INCRELEX, ALKINDI SPRINKLE, DESMODA, GALZIN, HEMANGEOL, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone.
Brands & revenue mix
A treatment for adrenal insufficiency, noted as a primary driver of revenue growth.
Separate brand revenue is not available in this research.Source
A rare disease product launched in 2025.
Separate brand revenue is not available in this research.Source
A rare disease product launched in 2025.
Separate brand revenue is not available in this research.Source
A rare disease product launched in 2025.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
The company's revenue is derived from sales to a limited number of wholesale distributors and specialty pharmacies, which is typical for the rare disease pharmaceutical industry.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production of its pharmaceutical products.Source
Strengths
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Diluted weighted-average shares increased 21.9% year over year.
Compare per-share results with total earnings and inspect the equity footnote. A change in weighted-average shares does not by itself establish the cause, the number of shares issued today, or the economic effect of a split.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
35
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
65
Fair
Financial Strength
40
Business Quality / Moat
87
Management
80
Growth Quality
97
Risk / Durability
9
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
32
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
45/100
Building Historical Record
Model Score 45/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Debt service risk
- •M&A headline · Aug 5, 2026
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for ETON
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can ETON maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is ETON's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Does ETON's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What future growth or profitability would be needed to justify ETON's current valuation?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of ETON's score?
Essential Investment Snapshot
Wall Street Score
35
Opportunity Score
32
Market Cap
$1.46B
P/E Ratio
110.7
EPS
$0.47
52-Week High
$66.37
52-Week Low
$14.27
Beta
0.90
Intrinsic Value
$17.90
Analyst Target
$68.00
Shares Outstanding
26.9M
Total Revenue
$105.6M
Total Debt
$29.0M
Dividend
No current dividend
Liquidation Value / Share
$1.73
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for ETON
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~0.0x). Earnings may be strained to cover interest expense.
M&A headline · Aug 5, 2026
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001 — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireCommunity Sentiment
0 active · 0 total callsNo personal call yet on ETON.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Specialized sales force focused on pediatric endocrinology.
- +Portfolio of ten commercial rare disease products.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Drug Manufacturers - Specialty & Generic industry.
- −Dependence on third-party manufacturers for product supply.
- −Regulatory risks associated with FDA approval processes.
- −Diluted weighted-average shares increased 21.9% year over year.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
35
Sep 21, 2026
Change
+0.1
points
Current Score
35
Oct 1, 2026
Category Changes
ETON increased 0.1 points because overall fundamentals improved.
Projected Score
Projected Score
36
Projected Change
+0.4 points
Preliminary comparable-period financial changes suggest improvement of approximately 0.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
OvervaluedCurrent Price
$51.16
Model Intrinsic Value
$17.90
Difference
+$33.26
+185.8% vs IV
Margin of Safety
-185.8%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +104.9%
Revenue changed sharply from 2024 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $105.6M | $80.0M | $39.0M | $31.6M | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $44.5M | $37.2M | $15.6M | $10.6M | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $61.1M | $42.7M | $23.4M | $21.1M | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $5.8M | $7.8M | $3.3M | $3.3M | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $39.0M | $35.8M | $22.8M | $18.9M | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $43.9M | $42.7M | $26.0M | $22.3M | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $18.6M | $4.3M | -$657K | $212K | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $17.2M | $72K | -$2.6M | -$1.2M | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $2.7M | $4.8M | $2.0M | $1.1M | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $12.8M | -$4.6M | -$3.8M | -$689K | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $63K | $43K | $15K | $247K | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $12.7M | -$4.6M | -$3.8M | -$936K | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $0.46 | $-0.17 | $-0.15 | $-0.04 | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 27.64M | 26.91M | 25.89M | 25.64M | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 32.79M | 26.91M | 25.89M | 25.65M | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$37.6M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$0.35
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-5.5%
Cash Change
+5.8%
Margin Change
+44.5 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included revenue growth, cash levels, debt levels, net income margin. Pressure indicators included EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 98.6%. EPS declined 464.2%. Cash increased 5.8%. Total debt declined 5.5%. Net income margin improved by 44.5 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
40
Smart Money
40
Number of Gurus
1
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Drug Manufacturers - Specialty & GenericNews
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
ETON Stock Surges 108% in Six Months: Here's What You Need to Know
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Has Consensus Price Target of $67.50 According to Brokerages
Rumor Mill · ETON
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial